BostonGene
PrivateLast Round
Series B
Apr 6, 2022
Est. Valuation
$2B
Total Funding Raised
$200M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BostonGene is a biotechnology company that develops an AI-powered, omnimodal analysis platform that integrates genomic, transcriptomic, immune, and clinical data to provide actionable insights for oncology drug development and personalized patient care.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Healthcare Analytics, Medical AI, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BostonGene Comparables
Compare BostonGene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tempus | 83% | |
| Caris Life Sciences | 80% | |
| ConcertAI | 76% |
BostonGene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 6, 2022 | ||||
| Series A | Apr 24, 2019 |
BostonGene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Industrial Partners | Series B |
| Impact Investment Exchange | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 55% MoM.
- May 17, 2026
Launched an AI foundation model for tumor and immune biology.
Recent news
Latest coverage and updates
- attends_eventSep 8, 2026
BostonGene Corporation attended event Society of Hematologic Oncology (SOHO) 2026 Annual Meeting on Sep 9th '26.
- partners_withJul 23, 2026
BostonGene Corporation partnered with Kyoto University on Jul 23rd '26.
- is_developingJul 22, 2026
BostonGene Corporation is developing AI model for tumor and immune biology.
- receives_awardJul 7, 2026
BostonGene Corporation received award Overall AI-based Analytics Company of the Year at 2026 AI Breakthrough Awards on Jul 7th '26.
- attends_eventJul 7, 2026
BostonGene Corporation attended event 2026 AI Breakthrough Awards on Jul 7th '26.
BostonGene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BostonGene's valuation, stock price, and market status.
Is BostonGene a public or private company?
BostonGene is a private company.
What is the current stock price of BostonGene?
BostonGene is a private company with no public stock price. No recent secondary market data is available.
How much is BostonGene worth (valuation)?
BostonGene's valuation is estimated at $1.0B based on funding round data.
Can I buy BostonGene stock?
BostonGene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was BostonGene's last funding round?
BostonGene's most recent funding round was Series B on April 6, 2022.
Who are the main investors in BostonGene?
Key investors in BostonGene include Japan Industrial Partners, Impact Investment Exchange.
Will BostonGene IPO soon?
No public IPO plans have been announced for BostonGene.
How can I track BostonGene secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BostonGene's secondary market activity and sign up for updates.